News Report says US biotech needs $15bn support to fend off China The US is close to falling behind China in biotech and the government should spend a minimum of $15bn over the next five years to support the sector.
News Chiesi backs growth plans with a €430m new plant in Italy Fast-growing pharma group Chiesi has revealed plans to spend €430m on a new therapeutics manufacturing facility at its site in Milan.
News AZ builds in China, as J&J ramps up its US investments AstraZeneca will open its sixth R&D centre in China, while J&J announces four new manufacturing facilities in the US in a major reshoring drive.
News UK is becoming an 'outlier' for pharma, hitting investment UK pharma leaders have renewed calls for a rethink by the government on levies imposed on medicine sales, saying investment is already being hit.
News MSD opens $1bn plant for HPV vaccine in the US MSD has opened the doors of a $1bn facility at its site in Durham, North Carolina, that will be used to produce its HPV vaccine Gardasil.
R&D On incentivisation and investment in rare disease R&D To mark Rare Disease Day, pharmaphorum spoke with Paola Pozzi, partner of telethon strategy at Sofinnova Partners, about the outlook for investment in this field of research.
News UK MHRA green lights AbbVie’s ELAHERE for ovarian cancer AbbVie has secured UK marketing authorisation for ELAHERE (mirvetuximab soravtansine), the first antibo
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face